Study to evaluate efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adult patients with severe asthma - WAYFINDER

Study identifier:D5180C00037

ClinicalTrials.gov identifier:NCT05274815

EudraCT identifier:2021-005457-85

CTIS identifier:N/A

Recruitment Complete

Official Title

A Multicentre, Single-arm, Phase 3b Efficacy and Safety Study of Tezepelumab 210 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Participants with Severe Asthma on High-dose Inhaled Corticosteroid plus Long-acting β2 Agonist and Long-term Oral Corticosteroid Therapy (WAYFINDER)

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

306

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 17 May 2022
Estimated Primary Completion Date: 12 Sept 2024
Estimated Study Completion Date: 12 Sept 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria